Galenica AG Reports Robust 5.5 % Revenue Growth to CHF 4.136 Billion
On 22 January 2026, Galenica AG announced a 5.5 % increase in consolidated revenue, reaching CHF 4 135.6 million for the year ended 31 December 2025. The milestone represents the highest turnover in the company’s history and confirms the firm’s trajectory of broad‑based, sustainable expansion.
Drivers of the Upswing
| Segment | YoY Growth | Key Contributions |
|---|---|---|
| Pharmacy Omni‑Channel | 4.9 % | 381 pharmacies (incl. 5 newly acquired Coop Vitality sites) delivered CHF 1 473.3 million in sales. |
| Wholesale | Continuous | Strengthened supplier relationships and increased volume in the pharmaceutical distribution arm. |
| Diagnostics | 1 % | New diagnostics offering added a modest but steady revenue stream. |
| Prescription Drugs | — | Strong demand for GLP‑1‑based weight‑loss medications and other prescription products. |
| Dietary Supplements | — | Growing consumer focus on health and wellness spurred sales. |
The pharmacy channel remains Galenica’s flagship business, with the network’s enhanced omnichannel capabilities—integrating physical stores with digital services—further solidifying its position as the first point of contact in Switzerland’s health system.
EBIT1 Guidance and Dividend Outlook
Galena’s CEO Marc Werner reaffirmed the 10‑12 % EBIT1 growth target for 2025, a forecast bolstered by the recent acquisition of Labor Team, which expanded the company’s diagnostic capabilities. The firm also reiterated a dividend policy of at least the previous year’s payout, underscoring its commitment to shareholder returns amid continued investment in growth initiatives.
Market Reaction and Share Performance
- Close (20 January 2026): CHF 96.10
- 52‑Week High (7 January 2026): CHF 100.40
- 52‑Week Low (7 April 2025): CHF 76.75
- Market Capitalisation: CHF 4.8 billion
- P/E Ratio: 24.95
The announcement has been well received by investors, who note the company’s ability to generate consistent revenue across multiple channels. Analyst sentiment remains bullish, citing Galenica’s resilient business model and its strategic positioning in the Swiss healthcare market.
Forward‑Looking Perspective
With a revenue base surpassing CHF 4 billion and a clear path to EBIT1 expansion, Galenica AG is poised to continue its upward trajectory. The company’s diversified portfolio—combining traditional pharmacy retail, wholesale distribution, and emerging diagnostics—provides a robust framework for capturing evolving consumer health needs. As the Swiss market continues to prioritize integrated health services, Galenica’s omnichannel approach positions it to lead the sector, sustain earnings growth, and deliver shareholder value in the coming years.
